Next Article in Journal
WDR36-Associated Neurodegeneration: A Case Report Highlights Possible Mechanisms of Normal Tension Glaucoma
Next Article in Special Issue
High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
Previous Article in Journal
Prevalence and Clinical Characteristics of Hearing Loss Caused by MYH14 Variants
Previous Article in Special Issue
Genetic and Genomic Pathways of Melanoma Development, Invasion and Metastasis
 
 
Article
Peer-Review Record

Structural Protein Analysis of Driver Gene Mutations in Conjunctival Melanoma

Genes 2021, 12(10), 1625; https://doi.org/10.3390/genes12101625
by Mak B. Djulbegovic 1, Vladimir N. Uversky 2,3, J. William Harbour 1, Anat Galor 1,4,5 and Carol L. Karp 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Genes 2021, 12(10), 1625; https://doi.org/10.3390/genes12101625
Submission received: 14 September 2021 / Revised: 5 October 2021 / Accepted: 12 October 2021 / Published: 15 October 2021
(This article belongs to the Special Issue Genetics and Genomics of Melanoma)

Round 1

Reviewer 1 Report

In this work, Djulbegovic et al evaluated 5 proteins that are associated with conjunctival melanoma using several (online) tools. They report on the intrinsically disordered protein regions (IDPR) and its protein-protein interactions (PPI). While the content is absolutely novel, and clearly written and presented, the rationale for this study is somewhat difficult to understand. Yes the reported genes are relevant for conjunctival melanoma, but the findings are based on non-conjunctival  material (as far as I understand), and only a theoretical claim is presented that future therapies could be aimed at these proteins. I would suggest to either rewrite the paper to a more general introduction into the relevance of IDPRs and PPI's for ocular oncologists (perhaps using conj mel as an example), or to provide the (currently missing) link between reported proteins and upcomming / suggested therapy.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The article by Djulbegovic et al. reports clearly, precisely and with absolute clinical application information about conjunctival melanoma. I appreciated the translational research and I suggest improving the clinical application. Figures are adapted and just some points needed to be improved.

 

  • Figure 1, correct caption
  • Material and method: provide a flowchart of your database research.
  • Figures 1 and 2 are well-presented
  • Add targeted therapies: read and cite

- Sun, J., Carr, M. J., & Khushalani, N. I. (2020). Principles of Targeted Therapy for Melanoma. The Surgical clinics of North America100(1), 175–188. https://doi.org/10.1016/j.suc.2019.09.013

Rossi, E., Maiorano, B. A., Pagliara, M. M., Sammarco, M. G., Dosa, T., Martini, M., Rindi, G., Bria, E., Blasi, M. A., Tortora, G., & Schinzari, G. (2019). Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. Frontiers in oncology9, 232. https://doi.org/10.3389/fonc.2019.00232

Demirci, H., Demirci, F. Y., Ciftci, S., Elner, V. M., Wu, Y. M., Ning, Y., Chinnaiyan, A., & Robinson, D. R. (2019). Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy. JAMA ophthalmology137(12), 1444–1448. https://doi.org/10.1001/jamaophthalmol.2019.4237

  • Line 148-150 report very fascinating items. Did you find the same IDPRs related to other tumours (or from the ectodermal structures)?

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop